Metformin suppresses high glucose-induced poly(adenosine diphosphate-ribose) polymerase overactivation in aortic

Meriem Mahrouf-Yorgov1, Nicolas Marie, Didier Borderie

  • 1EA 3617 Biochimie radicalaire et atteintes vasculaires, Université Paris Descartes, UFR des Sciences Pharmaceutiques et Biologiques, 4, avenue de l'Observatoire, F75006 Paris, France.

Insights

Metformin inhibits overactivation of poly(adenosine diphosphate-ribose) polymerase (PARP) in high glucose conditions. This mechanism involves blocking protein kinase C-dependent NAD(P)H oxidase activation, potentially explaining metformin

Area of Science:

  • Endocrinology and Metabolism
  • Vascular Biology
  • Biochemistry

Background:

  • Poly(adenosine diphosphate-ribose) polymerase (PARP) overactivation contributes to diabetes complications via vascular dysfunction.
  • Metformin exhibits vasculoprotective effects independent of its glucose-lowering action.

Purpose of the Study:

  • To investigate metformin's ability to inhibit high glucose-induced PARP activation in endothelial cells.
  • To elucidate the mechanisms underlying metformin's inhibitory effect on PARP.

Main Methods:

  • Assessed PARP activity using the CELISA method.
  • Evaluated poly(ribosyl)ated protein polymer accumulation via immunofluorescence.
  • Measured peroxynitrite anion production and p47phox subunit expression (NAD(P)H oxidase).

Main Results:

  • Metformin (5.10(-5) mol/L) abolished PARP activation and reduced poly(ribosyl)ated protein accumulation.
  • Metformin decreased intracellular peroxynitrite levels and reversed p47phox overexpression.
  • These effects were comparable to those of protein kinase C and NAD(P)H oxidase inhibitors.

Conclusions:

  • Metformin inhibits glucose-induced PARP activation by blocking a protein kinase C-dependent NAD(P)H oxidase pathway.
  • Metformin's vascular benefits in diabetes may stem from inhibiting PARP overactivation.
  • This study provides mechanistic insight into metformin's vasculoprotective properties.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...